Israel’s Teva has bought US biotech Auspex for $3.2 billion and acquires Auspex’s portfolio of innovative medicines for people who live with movement disorders. Auspex also has pipeline treatments for Huntington’s disease, Parkinson’s, dyskensia and Tourette’s syndrome.
http://www.tevapharm.com/news/?itemid={F45C98FD-CEA7-48C4-B9CB-A6BD00D0BEDB}